A TD Cowen analyst has recommended Aurora Cannabis shareholders accept Organigram's $561 million takeover offer, downgrading Aurora to 'Sell' and aligning its price target with the offer. This recommendation provides a clearer path for Aurora shareholders amidst a competing hostile bid, highlighting the strategic combination of international medical, Canadian recreational, and European cannabis operations.
TD Cowen analyst Derek Lessard has advised Aurora Cannabis shareholders to accept Organigram Global's $561 million acquisition offer, announced on November 3, 2026. This recommendation comes with a downgrade of Aurora Cannabis to 'Sell' from 'Buy' and a price target adjustment to $7.80, matching the offer price. The analyst believes this deal offers a more certain path to value realization for Aurora shareholders, providing options for cash, Organigram shares, or a combination, and crucially, helps avoid the risks associated with Curaleaf's competing hostile bid. The proposed merger aims to create a diversified cannabis entity by combining Aurora's international medical operations with Organigram's Canadian recreational business and Sanity Group's European platform. This is a significant development for ACB shareholders, who are being guided towards a specific outcome, potentially limiting short-term volatility related to the bidding war but capping upside at the offer price. For OGI, this analyst support is a positive signal for their acquisition strategy, while CURLF faces increased pressure on its hostile bid.